These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 24094894)
1. Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT; Waller EK; Nooka A; Flowers CR; Lonial S Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):657-63. PubMed ID: 24094894 [TBL] [Abstract][Full Text] [Related]
2. Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK Leuk Lymphoma; 2006 Oct; 47(10):2155-62. PubMed ID: 17071490 [TBL] [Abstract][Full Text] [Related]
3. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961 [TBL] [Abstract][Full Text] [Related]
4. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639 [TBL] [Abstract][Full Text] [Related]
7. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626 [TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680 [TBL] [Abstract][Full Text] [Related]
9. ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Labrador J; Cabrero-Calvo M; Pérez-López E; Mateos MV; Vázquez L; Caballero MD; García-Sanz R Ann Hematol; 2014 Oct; 93(10):1745-53. PubMed ID: 24863692 [TBL] [Abstract][Full Text] [Related]
10. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633 [TBL] [Abstract][Full Text] [Related]
11. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. Moore S; Kayani I; Peggs K; Qian W; Lowry L; Thomson K; Linch DC; Ardeshna K Br J Haematol; 2012 Jun; 157(5):543-52. PubMed ID: 22429186 [TBL] [Abstract][Full Text] [Related]
12. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567 [TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029 [TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099 [TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354 [TBL] [Abstract][Full Text] [Related]
16. Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. Sibon D; Ertault M; Al Nawakil C; de Bazelaire C; Franchi P; Brière J; de Kerviler E; Beranger N; Thieblemont C; Brice P Br J Haematol; 2011 Apr; 153(2):191-8. PubMed ID: 21385169 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Martínez C; Díaz-López A; Rodriguez-Calvillo M; García-Sanz R; Terol MJ; Pérez-Ceballos E; Jiménez MJ; Cantalapiedra A; Domingo-Domenech E; Rodriguez MJ; Sampol A; Espeso M; López FJ; Briones J; García JF; Sureda A; Br J Haematol; 2016 Sep; 174(6):859-67. PubMed ID: 27185197 [TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma. William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781 [TBL] [Abstract][Full Text] [Related]
19. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant. Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455 [TBL] [Abstract][Full Text] [Related]
20. Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide. Lee YG; Kwon JH; Kim I; Yoon SS; Lee JS; Park S Eur J Haematol; 2014 Jun; 92(6):478-84. PubMed ID: 24460733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]